These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 8941009

  • 41. Diagnostic value of prostatic acid phosphatase and prostate-specific antigen in patients with prostatic cancer.
    Pagani F, Zambolin T, Bonora R, Panteghini M.
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):85-7. PubMed ID: 1709211
    [Abstract] [Full Text] [Related]

  • 42. The efficacy of serum prostate specific antigen as a tumour marker in prostatic carcinoma: a comparison with serum acid phosphatase.
    Cooke RR, Nacey JN, Beeston RE, Delahunt B.
    N Z Med J; 1992 Sep 09; 105(941):345-7. PubMed ID: 1279493
    [Abstract] [Full Text] [Related]

  • 43. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A, Simşek F, Ilker Y, Türkeri L, Ercan H.
    Int Urol Nephrol; 1993 Sep 09; 25(3):271-8. PubMed ID: 7693607
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. [Prostatic specific antigen and prostatic pathology. Value of preoperative blood assay. Preliminary study apropos of 709 case reports].
    Bordes M, Brunet-Lecomte P, Dusserre P, Dusserre-Guion L, Michiels-Marzais D, Morlevat F, Peny J, Roignot P, Colas JM, Ferry N.
    Ann Urol (Paris); 1989 Sep 09; 23(4):295-300. PubMed ID: 2480077
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma.
    Cipolla BG, Ziade J, Bansard JY, Moulinoux JP, Staerman F, Quemener V, Lobel B, Guillé F.
    Cancer; 1996 Sep 01; 78(5):1055-65. PubMed ID: 8780544
    [Abstract] [Full Text] [Related]

  • 54. [Prostate-specific antigen (PSA): diagnostic and prognostic implications in the evaluation of carcinoma of the prostate].
    Lo Cigno M, Montanari F, Bercovich E, Soli M, Emili E, Dal Pozzo C, Platè L, Bianchi D.
    Arch Ital Urol Nefrol Androl; 1989 Mar 01; 61(1):29-36. PubMed ID: 2469127
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis.
    Izumi K, Mizokami A, Itai S, Shima T, Shigehara K, Miwa S, Maeda Y, Konaka H, Koh E, Namiki M.
    BJU Int; 2012 Feb 01; 109(3):394-400. PubMed ID: 21599822
    [Abstract] [Full Text] [Related]

  • 58. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan.
    Kosuda S, Yoshimura I, Aizawa T, Koizumi K, Akakura K, Kuyama J, Ichihara K, Yonese J, Koizumi M, Nakashima J, Fujii H.
    Cancer; 2002 Feb 15; 94(4):964-72. PubMed ID: 11920464
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.